Page 5,578«..1020..5,5775,5785,5795,580..5,5905,600..»

UH Case Medical Center awarded highest certification as Comprehensive Stroke Center

Posted: Published on March 14th, 2013

Public release date: 13-Mar-2013 [ | E-mail | Share ] Contact: George Stamatis george.stamatis@uhhospitals.org 216-844-3667 University Hospitals Case Medical Center University Hospitals (UH) Case Medical Center has become the first hospital in Northeast Ohio and 19th in the nation to achieve The Joint Commission's standards for Comprehensive Stroke Center Certification, joining an elite group of providers focused on complex stroke care. Comprehensive stroke centers are recognized as industry leaders and are responsible for setting the national agenda in all aspects of stroke care and prevention. The recognition comes from The Joint Commission, the nation's oldest and largest standards-setting and accrediting body in health care, and the American Heart Association/American Stroke Association. Comprehensive Stroke Center Certification recognizes those hospitals that have state-of-the-art infrastructure, staff and training to receive and treat patients with the most complex strokes. UH Case Medical Center underwent a rigorous onsite review in November. Joint Commission experts reviewed UH Case Medical Center's compliance with the Comprehensive Stroke Center standards and requirements including advanced imaging capabilities, 24/7 availability of specialized treatments, and staff with the unique education and competencies to care for complex stroke patients. "By achieving this advanced certification, University Hospitals Case Medical Center has thoroughly demonstrated the … Continue reading

Comments Off on UH Case Medical Center awarded highest certification as Comprehensive Stroke Center

Robotic CORBYS platform uses patient feedback to help stroke victims walk again

Posted: Published on March 14th, 2013

Of the various effects that a stroke can have on a person, one of the most common is paralysis of one side of the body needless to say, this has a severe impact on the victims ability to walk. Treatment often consists of therapists retraining the persons body by repeatedly lifting their legs, guiding them through a proper walking pattern. The EU-funded CORBYS project aims to make such therapy easier for everyone involved by using a powered orthosis to move the patients legs in response to feedback from their brain. Currently still in development, the robotic CORBYS device consists of a wheeled platform, at the front of which is a sort of exoskeleton that attaches to the patients legs. A pivoting attachment at the waist of that orthosis links it with the rest of the platform, but allows the patient to turn easily. In the first phase of treatment, however, patients wouldnt use the platform. Instead, they would have sensors placed on key points of their body, then walk on a treadmill. After observing their stroke-altered gait, a therapist would step in and manually guide their legs through a corrected walking pattern. Feedback from the sensors would be used to … Continue reading

Comments Off on Robotic CORBYS platform uses patient feedback to help stroke victims walk again

Do Blood Thinners + Stroke Treatment = Danger?

Posted: Published on March 14th, 2013

Rate of brain hemorrhage in stroke patients given tPA isnt meaningfully higher Newswise ANN ARBOR, Mich. Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. But when one of them suffers a stroke caused by a clot in their brain, some emergency teams might hesitate to give a powerful clot-busting medication called tPA -- for fear that the combination of drugs might cause dangerous brain bleeding. Now, a University of Michigan Stroke Program study suggests this fear may be unfounded, at least for most patients taking common clot-preventing therapies. The study is based on data from 830 stroke patients who received tPA at any of the 28 Michigan hospitals that took part in two U-M-led studies. Just under half of them were on aspirin or clopidogrel (sold as Plavix) before they had their strokes. After adjusting for patients other characteristics, the researchers found no significant difference in the rate of brain bleeding seen on the patients brain scans -- even low-level bleeding that didnt cause symptoms. The results, published in the current issue of Academic Emergency Medicine, should help reassure emergency teams and patients alike … Continue reading

Comments Off on Do Blood Thinners + Stroke Treatment = Danger?

Do blood thinners + stroke treatment = danger? Study indicates the risk is low

Posted: Published on March 14th, 2013

Public release date: 12-Mar-2013 [ | E-mail | Share ] Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System ANN ARBOR, Mich. Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. But when one of them suffers a stroke caused by a clot in their brain, some emergency teams might hesitate to give a powerful clot-busting medication called tPA -- for fear that the combination of drugs might cause dangerous brain bleeding. Now, a University of Michigan Stroke Program study suggests this fear may be unfounded, at least for most patients taking common clot-preventing therapies. The study is based on data from 830 stroke patients who received tPA at any of the 28 Michigan hospitals that took part in two U-M-led studies. Just under half of them were on aspirin or clopidogrel (sold as Plavix) before they had their strokes. After adjusting for patients' other characteristics, the researchers found no significant difference in the rate of brain bleeding seen on the patients' brain scans -- even low-level bleeding that didn't cause symptoms. The results, published in the current issue of Academic Emergency Medicine, should … Continue reading

Comments Off on Do blood thinners + stroke treatment = danger? Study indicates the risk is low

Case Study: Telestroke Network hastens stroke treatment

Posted: Published on March 14th, 2013

In the UK strokes are becoming an increasing threat to our health. Every year an estimated 150,000 suffer from one and although seen as a disease only affecting the elderly, children and young people can also be victims. However, treatment has continued to improve thanks to strong research in the area and specialist consults knowing how to act fast when a patient is diagnosed. Now technology can have a part to play, as proved by the Cumbria and Lancashire Telestroke Network. In 2007 a national initiative was launched that said all patients should be able to access thrombolysis treatment which dissolves clots in the brain causing a stroke 24 hours a day, seven days a week. Although the intention was sound, not every area of the country had the facilities to make it happen. In Cumbria and Lancashire, only one in eight of our hospitals were able to offer the treatment and on a Monday to Friday office hours basis, meaning there were an awful lot of patients who could not access the service, said Kathy Blacker, director of the cardiac and stroke network in the region. We may have had the specialists but spread over such a large county … Continue reading

Comments Off on Case Study: Telestroke Network hastens stroke treatment

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama – Daniel Campbell – Video

Posted: Published on March 14th, 2013

Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama - Daniel Campbell After stem cell therapy at the Stem Cell Institute in Panama, Daniel Campbell describes how his condition has improved since his first treatment. Daniel is i... By: cellmedicine … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Stem Cell Treatment for Spinal Cord Injury at the Stem Cell Institute in Panama – Daniel Campbell – Video

InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

Posted: Published on March 14th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential is estimated to be over $10 billion. "The year 2012 has quickly become our most productive. We grew our research and development teams to support a pipeline that now exceeds seven new treatment options for neurotrauma, and weve established a GMP manufacturing facility capable of manufacturing our scaffold and hydrogels for human use, said Frank Reynolds, InVivo Chief Executive Officer. Were ready to start a first-in-man clinical trial of our biopolymer scaffolding in acute SCI patients, and we expect as many as five products to be either on the market or in clinical studies by the end of 2014. … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Posted: Published on March 14th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring together individuals with SCI, family members, healthcare professionals, and benefactors for a silent auction, dinner and dancing. This years gala marks the 21st anniversary of the Greater Boston Chapter. Weve worked for years to be ready to begin human studies and as we await word from the FDA regarding our application were proud to once again be a part of the RISE Above Paralysis Gala, said Frank Reynolds, InVivo Chief Executive Officer. This is the fourth year that weve been a premier sponsor, and we look forward to another evening celebrating the lives of those living with SCI. Said David Estrada, Director of … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Parkinson’s Shuffle Gait – Video

Posted: Published on March 14th, 2013

Parkinson's Shuffle Gait Short video for PTA 113. By: Taylor Richardson … Continue reading

Posted in Parkinson's Treatment | Comments Off on Parkinson’s Shuffle Gait – Video

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

Posted: Published on March 14th, 2013

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVA) today announced that 15 abstracts highlighting study results for Parkinsons disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT (rasagiline tablets), an MAO-B inhibitor for the treatment of PD, will be presented as part of the meetings Emerging Science program (formerly known as Late-Breaking Science) on Wednesday, March 20th at 5:45pm PST. We are pleased with the variety of topics and quality of research results that will be presented at AAN this year, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. Tevas legacy in CNS is grounded in our commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as RRMS and Parkinsons disease. Featured presentations include: Platform Presentation/Poster Session Details: AZILECT COPAXONE Laquinimod About Azilect AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in … Continue reading

Posted in Parkinson's Treatment | Comments Off on Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

Page 5,578«..1020..5,5775,5785,5795,580..5,5905,600..»